- Home
- NKTR
NKTR
Nektar Therapeutics
as 02-21-2025 4:00pm EST
Nektar Therapeutics is a biopharmaceutical company. It has wholly-owned research and development pipeline of investigational medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. In oncology, The company is focused on activating the immune system natural tumor-fighting mechanisms, and it will be studying several immuno-oncology drug candidates in the clinic for a variety of cancer indications. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, the company believes selective immuno-modulators can be useful in addressing viral infections in people. The group derives revenue from the United States and the Rest of the World.
| Founded: | 1990 | Country: | United States |
| Employees: | N/A | City: | SAN FRANCISCO |
| Market Cap: | 247.9M | IPO Year: | 1994 |
| Target Price: | $4.50 | AVG Volume (30 days): | 3.0M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.84 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.63 - $1.93 | Next Earning Date: | 03-03-2025 |
| Revenue: | $93,137,000 | Revenue Growth: | 5.53% |
| Revenue Growth (this year): | 12.15% | Revenue Growth (next year): | -13.98% |
Stock Insider Trading Activity of Nektar Therapeutics (NKTR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Wilson Mark Andrew | NKTR | Chief Legal Officer | Dec 23 '24 | Sell | $0.90 | 49,962 | $44,800.20 | 351,892 | |
| Zalevsky Jonathan | NKTR | Chief R&D Officer | Dec 19 '24 | Sell | $0.94 | 51,115 | $48,048.10 | 326,904 | |
| ROBIN HOWARD W | NKTR | President & CEO | Dec 17 '24 | Sell | $1.00 | 132,030 | $131,649.60 | 1,195,710 |
Latest Nektar Therapeutics News
NKTR Breaking Stock News: Dive into NKTR Ticker-Specific Updates for Smart Investing
MT Newswires
12 days ago
Nektar Says FDA Grants Fast-Track Designation to Atopic Dermatitis Treatment
PR Newswire
12 days ago
Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis
Zacks
15 days ago
Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround
Zacks
19 days ago
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
Zacks
22 days ago
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
Zacks
22 days ago
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
Zacks
a month ago
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?
PR Newswire
a month ago
Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AD Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Moderate-to-Severe Atopic Dermatitis
Compare NKTR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NKTR Nektar Therapeutics - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.